NICE draft guidance on Sovaldi for Hepatitis C - Gilead Sciences.
NICE in draft guidance now states that it is now planning to recommend the Solaldi (sofosbuvir) from Gilead Sciences, in combination with peginterferon alfa and ribavirin for treating: genotype 1 chronic Hepatitis C in adults; genotype 3 chronic Hepatitis C in adults with cirrhosis; and genotype 3 chronic Hepatitis C in adults without cirrhosis only if they have had treatment for hepatitis C before. It does not recommend Sovaldi in combination with peginterferon alfa and ribavirin for treating genotype 4, 5 and 6 chronic Hepatitis C in adults.
In combination with ribavirin alone, NICE plans to recommend�s Sovaldi�s use as an option for treating: genotype 2 chronic Hepatitis C in adults, only if they have had treatment for chronic Hepatitis C before and are intolerant to or ineligible for interferon therapy, or if they have had treatment for chronic Hepatitis C before, regardless of interferon eligibility; and for treating genotype 3 chronic Hepatitis C only in adults with cirrhosis. It does not plan to recommend Sovaldi, in combination with ribavirin alone, for treating adults with genotype 1,4, 5 and 6 chronic Hepatitis C.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins